Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study
Benzinga Newsdesk 2 years ago
NewsFDA
Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver
- Data and Safety Monitoring Board (DSMB) recommends the continuation, without modifications, of the adaptive Phase 2b/3 NAVIGATE study of belapectin in metabolic dysfunction-associated steatohepatitis (MASH) liver cirrhosis
- Fifth positive recommendation further supports favorable tolerability and safety profile of belapectin
- Interim Phase 2b efficacy readout anticipated in Q4 2024